Dr. Kristeleit on the Efficacy of Rucaparib in Ovarian Cancer

Video

Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the efficacy of rucaparib in the treatment of patients with ovarian cancer.

Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the efficacy of rucaparib in the treatment of patients with ovarian cancer.

According to the results of an analysis of 2 phase II trials presented at the 2016 ESMO Congress, the majority of heavily pretreated patients with high-grade ovarian cancer and germline or somatic BRCA mutations showed a durable response to rucaparib.

Kristeleit explains that the radiological cutoff for identifying which patients "respond" is determined by tumor shrinkage of at least 30%. However, she says, there were still patients in this analysis whose tumors shrunk by approximately 28% or 29%, and while they do not necessarily meet the specified cutoff, it is important to note that these individuals are still benefiting from the treatment in a significant way.

Moreover, at 6 months, 79% of patients were progression-free, according to Kristeleit. At 12 months, that number was still over 40%, and at nearly 2 years, approximately 10% of women still had not progressed. This is exciting data, particularly for this heavily pretreated, relatively platinum-sensitive patient population.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,